NASDAQ: KYTXKyverna Therapeutics Inc Stock
$1.86+0.03 (+1.64%)
Updated Apr 17, 2025
KYTX Price
$1.86
Fair Value Price
$2.31
Market Cap
$80.38M
52 Week Low
$1.78
52 Week High
$19.67
P/E
-0.56x
P/B
0.3x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$127.48M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.14
Operating Cash Flow
-$114M
Beta
1.25
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KYTX Overview
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KYTX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KYTX
Ranked#445 of 463
Ranked#445 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important KYTX news, forecast changes, insider trades & much more!
KYTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KYTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KYTX ($1.86) is undervalued by 19.32% relative to our estimate of its Fair Value price of $2.31 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
KYTX ($1.86) is not significantly undervalued (19.32%) relative to our estimate of its Fair Value price of $2.31 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KYTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KYTX due diligence checks available for Premium users.
Valuation
KYTX fair value
Fair Value of KYTX stock based on Discounted Cash Flow (DCF)
Price
$1.86
Fair Value
$2.31
Undervalued by
19.32%
KYTX ($1.86) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KYTX ($1.86) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KYTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KYTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.56x
Industry
-177.72x
Market
27.98x
KYTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.3x
Industry
4.05x
KYTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KYTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$37.5M
Profit Margin
0%
KYTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$304.6M
Liabilities
$38.1M
Debt to equity
0.14
KYTX's short-term assets ($290.60M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KYTX's short-term assets ($290.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KYTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$37.1M
Investing
$29.2M
Financing
-$215.0k
KYTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KYTX vs Biotech Stocks
Kyverna Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.